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Post-hoc secondary analysis of data from our recent Edinburgh and Lothians Viral Intervention Study (ELVIS) pilot randomised controlled trial (RCT) indicates that hypertonic saline nasal irrigation and gargling (HSNIG) reduced the duration of coronavirus upper respiratory tract infection (URTI) by 
an average of two-and-a-half days. As such, it may offer a potentially safe, effective and scalable interven-
tion in those with Coronavirus Disease-19 (COVID-19) following infection with the betacoronavirus Se-
vere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [1].
ELVIS was undertaken in 66 adults with URTI. Results have been reported in detail elsewhere [2]. Brief-
ly, volunteers with URTI were within 48 hours of symptom onset randomised to intervention (n = 32) or 
control (n = 34) arms. The intervention arm made hypertonic saline at home and performed HSNIG as 
many times as needed (maximum of 12 times/day). Control arm participants dealt with their URTI as 
they normally did. Nose swabs collected at recruitment and first thing in the morning on four consecu-
tive days were sent to the laboratory for testing. Both arms kept a diary (which included the Wisconsin 
Upper Respiratory Symptom Survey-21 questionnaire) for a maximum of 14 days or until they were well 
for two consecutive days. Follow-up data were available for 92% of individuals (intervention arm: n = 30; 
control arm: n = 31). HSNIG reduced the duration of URTI by 1.9 days (P = 0.01), over-the-counter med-
ication use by 36% (P = 0.004), transmission within household contacts by 35% (P = 0.006) and viral 
shedding by ≥0.5 log
10
/d (P = 0.04) in the intervention arm when compared to controls [2].
We also recently reported that epithelial cells mount an antiviral effect by producing hypochlorous acid 
(HOCl) from chloride ions [3]. HOCl is the active ingredient in bleach. Epithelial cells have this innate 
antiviral immune mechanism to clear viral infections. Since bleach is effective against all virus types [4], 
we tested to see if a range of DNA, RNA, enveloped and non-enveloped viruses were inhibited in the 
presence of chloride ions supplied via salt (NaCl). All the viruses 
we tested were inhibited in the presence of NaCl. The human vi-
ruses we tested were: DNA/enveloped: herpes simplex virus; 
RNA/enveloped: human coronavirus 229E (HCoV-229E), respi-
ratory syncytial virus, influenza A virus; and RNA/non-envel-
oped: coxsackievirus B3 [3].
In COVID-19, high titres of SARS-CoV-2 are detectable in the 
upper respiratory tract of asymptomatic and symptomatic indi-
viduals [5]. The titres are higher in the nose than the throat sug-
gesting measures that control the infection and viral shedding 
will help reduce transmission [5]. In the context of the COVID-19 
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pandemic, we have undertaken a post-hoc 
re-analysis of the ELVIS data with a focus on 
those infected with coronaviruses. Coronavi-
ruses were the second most common cause of 
URTI (after rhinoviruses). Fifteen individuals 
were infected by a coronavirus: 7 in the inter-
vention arm, 8 in the control arm. In the in-
tervention arm, four participants were infected 
by an alphacoronavirus (HCoV 229E = 3, 
HCoV NL63 = 1) and three by a betacoronavi-
rus (HCoV HKU1 = 3). In the control arm, two 
were infected by an alphacoronavirus (HCoV 
NL63 = 2) and six by a betacoronavirus (HCoV 
OC43 = 1, HCoV HKU1 = 5). An individual in 
the control arm with HCoV HKU1 had dual 
infection with rhinovirus.
The duration of illness was lower in the inter-
vention arm compared to the control arm in 
the subset of patients infected with coronavi-
rus (mean days (SD): 5.6 (1.4) vs 8.1 (2.9)). 
Using a two-sample t test, this was difference of -2.6 days (95% confidence interval (CI) = -5.2, 0.05; 
P = 0.054). The difference in the duration of blocked nose was -3.1 days (95% CI = -6.0, -0.2; P = 0.04), 
cough -3.3 days (95% CI = -5.9, -0.7; P = 0.02) and hoarseness of voice -2.9 days (95% CI = -5.6, -0.3; 
P = 0.03) in favour of HSNIG (Table 1). The severity of symptoms in individuals in the two arms can be 
seen in Figure 1.
The individual in the control arm with a co-existing rhinovirus infection could have affected the results. 
Excluding this individual, the duration of illness in the control arm was a mean of 7.3 days (SD = 1.8). 
The impact on the intervention control comparison was to reduce the size of the difference to -1.7 days 
(95% CI = -3.6, 0.2; P = 0.07).
In the absence of a suitable antiviral agent or a vaccine, we need a safe and effective intervention that can 
be globally implemented. Our in-vitro data gives the evidence that NaCl has an antiviral effect that works 
across viral types. The findings from this post-hoc analysis of ELVIS need to be interpreted with caution. 
These data do however suggest that HSNIG may have a role to play in reducing symptoms and duration 
of illness in COVID-19.
It is unclear if hypertonic saline nasal irrigation and gar-
gling is also effective in COVID-19 caused by SARS-CoV-2; 
a trial is therefore urgently needed.
Photo: Nasal irrigation and gargling (from the ELVIS study video, used with permission).
Table 1. Number of days for self reported symptom improvement in the control and intervention arms infected by 
a coronavirus
Variable label TreaTmenT n mean SD Difference in mean (inTerVenTion – conTrol) (95% ci for Difference) P-Value
Blocked nose Intervention 7 4.0 2.2 -3.1 (-6.0, -0.2) 0.0362
Blocked nose Control 8 7.1 2.9
Chest congestion Intervention 7 1.9 1.2 -0.8 (-2.7, 1.2) 0.4056
Chest congestion Control 8 2.6 2.1
Cough Intervention 7 2.7 1.3 -3.3 (-5.9, -0.7) 0.0179
Cough Control 8 6.0 3.0
Head congestion Intervention 7 3.4 1.9 -1.9 (-5.0, 1.1) 0.1931
Head congestion Control 8 5.4 3.3
Hoarseness Intervention 7 2.4 1.6 -2.9 (-5.6, -0.3) 0.0325
Hoarseness Control 8 5.4 2.9
Scratchy throat Intervention 7 2.6 1.0 -2.1 (-5.1, 1.0) 0.1712
Scratchy throat Control 8 4.6 3.6
Sneezing Intervention 7 3.9 1.7 -1.0 (-3.8, 1.8) 0.4469
Sneezing Control 8 4.9 3.0
Sore throat Intervention 7 3.6 1.9 -1.1 (-4.4, 2.3) 0.5139
Sore throat Control 8 4.6 3.7
Runny nose Intervention 7 4.4 1.3 -1.6 (-4.1, 0.9) 0.1999
Runny nose Control 8 6.0 2.8
Feeling tired Intervention 7 3.6 1.8 -2.1 (-5.1, 1.0) 0.1671
Feeling tired Control 8 5.6 3.3
SD – standard deviation, CI – confidence interval
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Figure 1. Response to global severity question and severity of symptoms. Response from participants over the study 
period: Each line represents response of a participant over 14 days. Data are shown by treatment group (Top panel 
– Control Arm; Bottom panel – Intervention Arm). The global severity question was “How unwell do you feel 
today”. The responses were graded from 0 (Not unwell), 1 (very mildly), 3 (mildly), 5 (moderately) and 7 (severely 
unwell). Likewise, each symptom was graded 0 (no symptom) to 7 (severe). WURSS-21 Score was the sum of the 
severity of individual symptoms.
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